ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1836

Transcriptional Changes in the Formation of Tissue Resident Memory T Cells in the Joint

Yang Yang1, Yusuke Miyashita1, Vitor Aguiar1, Maria Gutierrez-Arcelus1, Kellen Winden2, Peter Nigrovic3 and Margaret Chang1, 1Boston Children's Hospital, Boston, MA, 2Boston Children's Hospital, Boston, MA, 3Boston Children's Hospital, Brookline, MA

Meeting: ACR Convergence 2024

Keywords: Gene Expression, Juvenile idiopathic arthritis, Mouse Models, RA, rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We previously demonstrated that joint-specific memory is mediated by CD8+ synovial resident memory T (TRM) cells that persist in arthritic joints during remission and can mediate joint-specific flares. Depleting TRM cells from the joint results in an attenuation of arthritis flares, suggesting that targeting TRM cells could be a novel option to alleviate pathogenesis and disease chronicity. However, little is known about the origin and differentiation of TRM cells in the joint. Here, we investigated the dynamic transcriptional changes of TRM cell formation in the joint during inflammation and remission.

Methods: We used a murine arthritis model where OT-I T cells were adoptively transferred into recipient mice and arthritis was induced by intraarticular ovalbumin injection. CD8 T cells were isolated from the synovium at several time points—days 3, 4, 5, 6, 7, and 8 during initiation and resolution of acute joint inflammation, and days 18 and 28 during arthritis remission. Transcriptomic profiles of sorted CD8+ T cells were acquired by 10x single-cell RNA sequencing and analyzed using Seurat and weighted gene co-expression network analysis packages. Trajectory analysis and cell ancestry of synovial TRM cells were computed with the Waddington Optimal Transport analysis package. We then evaluated the dynamic gene expression patterns in TRM cell differentiation in human synovium organoids in which TRM cells were derived from peripheral blood mononuclear cells.

Results: We identified a group of synovial CD8 T cells with a TRM cell gene expression signature that was present in the synovium at Days 18 and 28 of arthritis remission. Trajectory analysis revealed that synovial TRM cells derived from both central memory T cells and effector memory T cells, and we confirmed the antigen-specificity of both the progenitors and TRM cells through matched TCR sequencing. We identified four distinct patterns of gene expression changes during TRM cell formation—1) genes expressed during acute arthritis that are downregulated during remission; 2) genes that show low expression during acute arthritis and are upregulated during remission (i.e. Runx3); 3) genes that are gradually upregulated through the entire time course; 4) genes that highly upregulated during the later phases of acute inflammation and then show moderate expression during remission (i.e. Zfp683, Itga1, Il15ra).

Conclusion: Our studies suggest that synovial CD8 TRM cells are derived from antigen-specific circulating effector cells. The various patterns of gene expression changes during TRM cell development may reflect differing roles of these canonical TRM cell genes in TRM cell formation. Targeting these TRM cell differentiation pathways could provide a novel therapeutic approach to joint-specific memory and chronic arthritis.


Disclosures: Y. Yang: None; Y. Miyashita: None; V. Aguiar: None; M. Gutierrez-Arcelus: None; K. Winden: None; P. Nigrovic: American Academy of Pediatrics, 9, Bristol-Myers Squibb(BMS), 5, Century Therapeutics, 2, Edelweiss Immuno, 8, Fresh Tracks Therapeutics, 2, Merck/MSD, 2, Monte Rosa Therapeutics, 2, Novartis, 2, Pfizer, 2, 5, Qiagen, 2, Sobi, 2, UpToDate, 9; M. Chang: None.

To cite this abstract in AMA style:

Yang Y, Miyashita Y, Aguiar V, Gutierrez-Arcelus M, Winden K, Nigrovic P, Chang M. Transcriptional Changes in the Formation of Tissue Resident Memory T Cells in the Joint [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/transcriptional-changes-in-the-formation-of-tissue-resident-memory-t-cells-in-the-joint/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transcriptional-changes-in-the-formation-of-tissue-resident-memory-t-cells-in-the-joint/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology